Antibody-drug conjugates (ADCs) comprise an antibody, a linker, and a cytotoxic active payload. Compared to traditional chemotherapy, ADCs that target tumors are expected to mitigate systemic toxic effects, provide a wider therapeuticRead More…
Antigen Target Selection A major challenge in developing antibody-drug conjugates (ADCs) for cancer lies in the identification and validation of sufficient antigen targets for the monoclonal antibody component. Several factors need toRead More…
Nucleic acid drugs are a frontier field in the development of biomedicine, and the targeted delivery system of nucleic acid drugs is both a difficult and important point. At present, small nucleicRead More…
Antibody-drug conjugates, often referred to as ADCs, are a type of dual-targeted therapeutic. They consist of three key components: an antibody, a payload, and a linker. The antibody determines the target disease,Read More…
The development trends of the next generation of ADC (antibody-drug conjugate) drugs can be observed to show improved specificity and cytotoxicity compared to earlier generations, driven by technological advancements. However, it’s importantRead More…
ADC (antibody-drug conjugate) has emerged as a promising class of anti-cancer drugs, with over a dozen ADC drugs currently approved for the treatment of various types of cancer patients. Traditional ADCs utilizeRead More…
In recent years, the development of antibody-drug conjugate (ADC) therapies has flourished, leading to significant advancements in treating solid tumors. The FDA has approved six solid tumor ADCs so far—Sacituzumab govitecan (SG),Read More…
ADC has established a solid position in the oncology pharmacopoeia. Over 1,500 clinical trials of ADCs are listed on clinicaltrials.gov, and an increasing number of drugs are entering clinical trials. It canRead More…
Like most drugs, the development interruption of ADCs is typically due to a lack of efficacy, safety issues, commercial considerations, or a combination of these factors. Since 2000, among the 97 ADCsRead More…
In 1913, the renowned German chemist Paul Ehrlich introduced the concept of the “magic bullet”, which is considered the earliest description of ADC drugs. In 2000, the FDA approved Mylotarg, the firstRead More…